Citius Pharmaceuticals, Inc. (CTXR) vs Dare Bioscience, Inc. (DARE)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Dare Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.50HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
DARE
Dare Bioscience, Inc.
$0.84HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
Total return — CTXR vs DARE
growth of $100 · dividends reinvested · last 10yCTXR -99.8% (-45.7%/yr)DARE -99.3% (-39.1%/yr)DARE compounded faster over this window
CTXR DARE
CTXR vs DARE: by the numbers
- •CTXR is the larger company ($14M vs $13M market cap).
- •Both run net losses; CTXR's is the smaller (-651.27% vs -804.37% net margin).
Metrics side by side
Valuation
| Metric | CTXR | DARE |
|---|---|---|
| P/S ratio | 1.93 | 9.17 |
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | CTXR | DARE |
|---|---|---|
| Gross margin | 0.00% | -137.55% |
| Operating margin | 0.00% | -1315.51% |
| Net margin | -651.27% | -804.37% |
| ROE | -69.47% | N/A |
| ROIC | -67.62% | -203.50% |
Growth (annualized)
| Metric | CTXR | DARE |
|---|---|---|
| Total return CAGR (5Y) | -60.04% | -46.35% |
Frequently asked
- How have CTXR and DARE total returns compared?
- Over the past 10 years, CTXR delivered -46.34% and DARE delivered -39.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.